Resveratrol inhibits prostaglandin formation in IL-1β-stimulated SK-N-SH neuronal cells

Journal of Neuroinflammation

Volumn 6, Issue , 2009, Pages 26-

  Wendeburg, Lena ^a,b   de Oliveira, Antonio C P ^a   Bhatia, Harsharan S ^a   Candelario Jalil, Eduardo ^c   Fiebich, Bernd L ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b VIVACELL BIOTECHNOLOGY GMBH   (Germany)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FREE RADICAL; INTERLEUKIN 1BETA; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; RESVERATROL;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PROSTAGLANDIN SYNTHESIS; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN SYNTHESIS INHIBITION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CELLS, CULTURED; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; ISOENZYMES; MICROGLIA; NEURONS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; RATS; STILBENES;

EID: 70449457232     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-6-26     Document Type: Article

References (44)

1. Murakami M, Kudo I. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog Lipid Res 2004, 43:3-35. 10.1016/S0163-7827(03)00037-7, 14636669.
2. Chaudhry UA, Zhuang H, Crain BJ, Dore S. Elevated microsomal prostaglandin-E synthase-1 in Alzheimer's disease. Alzheimers Dement 2008, 4:6-13. 10.1016/j.jalz.2007.10.015, 2500207, 18631945.
3. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004, 63:901-910.
4. Anekonda TS. Resveratrol--a boon for treating Alzheimer's disease?. Brain Res Rev 2006, 52:316-326. 10.1016/j.brainresrev.2006.04.004, 16766037.
5. Fiebich BL, Lieb K, Kammerer N, Hull M. Synergistic inhibitory effect of ascorbic acid and acetylsalicylic acid on prostaglandin E2 release in primary rat microglia. J Neurochem 2003, 86:173-178. 10.1046/j.1471-4159.2003.01822.x, 12807437.
6. Bosetti F, Rintala J, Seemann R, Rosenberger TA, Contreras MA, Rapoport SI, Chang MC. Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Mol Psychiatry 2002, 7:845-850. 10.1038/sj.mp.4001111, 12232777.
7. Bradbury DA, Corbett L, Knox AJ. PI 3-kinase and MAP kinase regulate bradykinin induced prostaglandin E(2) release in human pulmonary artery by modulating COX-2 activity. FEBS Lett 2004, 560:30-34. 10.1016/S0014-5793(04)00064-X, 14987993.
8. Cuendet M, Mesecar AD, DeWitt DL, Pezzuto JM. An ELISA method to measure inhibition of the COX enzymes. Nat Protoc 2006, 1:1915-1921. 10.1038/nprot.2006.308, 17487176.
9. Wu D, Mura C, Beharka AA, Han SN, Paulson KE, Hwang D, Meydani SN. Age-associated increase in PGE2 synthesis and COX activity in murine macrophages is reversed by vitamin E. Am J Physiol 1998, 275:C661-668.
10. Zhang MZ, Harris RC, McKanna JA. Regulation of cyclooxygenase-2 (COX-2) in rat renal cortex by adrenal glucocorticoids and mineralocorticoids. Proc Natl Acad Sci USA 1999, 96:15280-15285. 10.1073/pnas.96.26.15280, 24811, 10611376.
11. Fremont L. Biological effects of resveratrol. Life Sci 2000, 66:663-673. 10.1016/S0024-3205(99)00410-5, 10680575.
12. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990, 87:9383-9387. 10.1073/pnas.87.23.9383, 55169, 2123555.
13. Pratico D, Lawson JA, FitzGerald GA. Cyclooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2 alpha. J Biol Chem 1995, 270:9800-9808. 10.1074/jbc.270.17.9800, 7730359.
14. Candelario-Jalil E, de Oliveira AC, Graf S, Bhatia HS, Hull M, Munoz E, Fiebich BL. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation 2007, 4:25. 10.1186/1742-2094-4-25, 2100038, 17927823.
15. Candelario-Jalil E, Akundi RS, Bhatia HS, Lieb K, Appel K, Munoz E, Hull M, Fiebich BL. Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E2 production. J Neuroimmunol 2006, 174:39-51. 10.1016/j.jneuroim.2006.01.003, 16529823.
16. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998, 95:13313-13318. 10.1073/pnas.95.22.13313, 23795, 9789085.
17. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006, 5:493-506. 10.1038/nrd2060, 16732220.
18. Mokni M, Elkahoui S, Limam F, Amri M, Aouani E. Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat. Neurochem Res 2007, 32:981-987. 10.1007/s11064-006-9255-z, 17401679.
19. Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, Sun GY, Sun AY. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 2002, 958:439-447. 10.1016/S0006-8993(02)03543-6, 12470882.
20. Pham-Marcou TA, Beloeil H, Sun X, Gentili M, Yaici D, Benoit G, Benhamou D, Mazoit JX. Antinociceptive effect of resveratrol in carrageenan-evoked hyperalgesia in rats: prolonged effect related to COX-2 expression impairment. Pain 2008, 140:274-283. 10.1016/j.pain.2008.08.010, 18814970.
21. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 2009, 54:111-118. 10.1016/j.neuint.2008.10.008, 19041676.
22. Tsai SH, Lin-Shiau SY, Lin JK. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br J Pharmacol 1999, 126:673-680. 10.1038/sj.bjp.0702357, 1565862, 10188978.
23. Gao X, Xu YX, Janakiraman N, Chapman RA, Gautam SC. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem Pharmacol 2001, 62:1299-1308. 10.1016/S0006-2952(01)00775-4, 11705464.
24. Marier JF, Chen K, Prince P, Scott G, del Castillo JR, Vachon P. Production of ex vivo lipopolysaccharide-induced tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 is suppressed by trans-resveratrol in a concentration-dependent manner. Can J Vet Res 2005, 69:151-154. 1142184, 15971681.
25. Zhong M, Cheng GF, Wang WJ, Guo Y, Zhu XY, Zhang JT. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine 1999, 6:79-84.
26. Bastianetto S, Zheng WH, Quirion R. Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br J Pharmacol 2000, 131:711-720. 10.1038/sj.bjp.0703626, 1572384, 11030720.
27. Han YS, Zheng WH, Bastianetto S, Chabot JG, Quirion R. Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol 2004, 141:997-1005. 10.1038/sj.bjp.0705688, 1574264, 15028639.
28. Okawara M, Katsuki H, Kurimoto E, Shibata H, Kume T, Akaike A. Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem Pharmacol 2007, 73:550-560. 10.1016/j.bcp.2006.11.003, 17147953.
29. Bureau G, Longpre F, Martinoli MG. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J Neurosci Res 2008, 86:403-410. 10.1002/jnr.21503, 17929310.
30. Sexton E, Van Themsche C, LeBlanc K, Parent S, Lemoine P, Asselin E. Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol Cancer 2006, 5:45. 10.1186/1476-4598-5-45, 1626081, 17044934.
31. Heynekamp JJ, Weber WM, Hunsaker LA, Gonzales AM, Orlando RA, Deck LM, Jagt DL. Substituted trans-stilbenes, including analogues of the natural product resveratrol, inhibit the human tumor necrosis factor alpha-induced activation of transcription factor nuclear factor kappaB. J Med Chem 2006, 49:7182-7189. 10.1021/jm060630x, 17125270.
32. Kim YA, Lim SY, Rhee SH, Park KY, Kim CH, Choi BT, Lee SJ, Park YM, Choi YH. Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in beta-amyloid-treated C6 glioma cells. Int J Mol Med 2006, 17:1069-1075.
33. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM, Dannenberg AJ. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998, 273:21875-21882. 10.1074/jbc.273.34.21875, 9705326.
34. Subbaramaiah K, Michaluart P, Chung WJ, Tanabe T, Telang N, Dannenberg AJ. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Ann N Y Acad Sci 1999, 889:214-223. 10.1111/j.1749-6632.1999.tb08737.x, 10668496.
35. Baolin L, Inami Y, Tanaka H, Inagaki N, Iinuma M, Nagai H. Resveratrol inhibits the release of mediators from bone marrow-derived mouse mast cells in vitro. Planta Med 2004, 70:305-309. 10.1055/s-2004-818940, 15095144.
36. Martin AR, Villegas I, Sanchez-Hidalgo M, de la Lastra CA. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 2006, 147:873-885. 10.1038/sj.bjp.0706469, 1760707, 16474422.
37. Murias M, Handler N, Erker T, Pleban K, Ecker G, Saiko P, Szekeres T, Jager W. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem 2004, 12:5571-5578. 10.1016/j.bmc.2004.08.008, 15465334.
38. Likhitwitayawuid K, Sawasdee K, Kirtikara K. Flavonoids and stilbenoids with COX-1 and COX-2 inhibitory activity from Dracaena loureiri. Planta Med 2002, 68:841-843. 10.1055/s-2002-34403, 12357401.
39. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 1999, 96:7220-7225. 10.1073/pnas.96.13.7220, 22058, 10377395.
40. Mancini JA, Blood K, Guay J, Gordon R, Claveau D, Chan CC, Riendeau D. Cloning, expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. J Biol Chem 2001, 276(6):4469-4475. 10.1074/jbc.M006865200, 11067848.
41. Riendeau D, Aspiotis R, Ethier D, Gareau Y, Grimm EL, Guay J, Guiral S, Juteau H, Mancini JA, Methot N, Rubin J, Friesen RW. Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg Med Chem Lett 2005, 15:3352-3355. 10.1016/j.bmcl.2005.05.027, 15953724.
42. Moreno JJ. Resveratrol modulates arachidonic acid release, prostaglandin synthesis, and 3T6 fibroblast growth. J Pharmacol Exp Ther 2000, 294:333-338.
43. Akundi RS, Candelario-Jalil E, Hess S, Hull M, Lieb K, Gebicke-Haerter PJ, Fiebich BL. Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia. Glia 2005, 51:199-208. 10.1002/glia.20198, 15800925.
44. Jin F, Wu Q, Lu YF, Gong QH, Shi JS. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur J Pharmacol 2008, 600:78-82. 10.1016/j.ejphar.2008.10.005, 18940189.